|
A Text Message Intervention to Minimize the Time Burden of Cancer Care
|
July 22, 2025
|
PC3I Authors Kerry Coughlin; Larry Shulman; Ronac Mamtani; Lindsey Zinck |
NEJM catalyst innovations in care delivery
|
|
Survival Trends in Urothelial Cancer Before and After ICIs and Antibody Drug Conjugates
|
July 9, 2025
|
PC3I Authors Teja Voruganti; Ronac Mamtani |
JAMA Network Open
|
|
“Off-Label” Use of Checkpoint Inhibitors in Patients With Negative or Unknown PD-L1 Status in Advanced Head and Neck Cancer
|
February 11, 2025
|
PC3I Authors Ronac Mamtani |
Journal of the National Comprehensive Cancer Network
|
|
Evolving racial/ethnic disparities in AML survival in the novel therapy era
|
January 31, 2025
|
PC3I Authors Catherine Lai; Ronac Mamtani |
Blood Advances
|
|
NCCN Guidelines® Insights: Bladder Cancer, Version 3.2024
|
May 16, 2024
|
PC3I Authors Ronac Mamtani |
Journal of the National Comprehensive Cancer Network : JNCCN
|
|
Bladder Cancer, Version 3.2024
|
May 16, 2024
|
PC3I Authors Ronac Mamtani |
Journal of the National Comprehensive Cancer Network : JNCCN
|
|
Racial Differences in Cutaneous Events Among Patients Receiving Enfortumab Vedotin
|
April 30, 2024
|
PC3I Authors Ronac Mamtani |
Clinical Genitourinary Cancer
|
|
Comparing survival in trial- versus routine-care advanced urothelial cancer patients on immune checkpoint blockade
|
April 29, 2024
|
PC3I Authors Lucy Wang; Ronac Mamtani |
Pharmacoepidemiology and Drug Safety
|
|
Real-world use, dose intensity, and adherence to enfortumab vedotin in locally advanced or metastatic urothelial cancer
|
March 19, 2024
|
PC3I Authors Ronac Mamtani |
Urologic Oncology
|
|
Cost-effectiveness of nivolumab versus surveillance for the adjuvant treatment of patients with urothelial carcinoma who are at high risk of recurrence: a US payer perspective
|
March 12, 2024
|
PC3I Authors Ronac Mamtani |
Journal of Medical Economics
|
|
Health-related Quality of Life in Patients with Previously Treated Advanced Urothelial Carcinoma from EV-301: A Phase 3 Trial of Enfortumab Vedotin Versus Chemotherapy
|
February 28, 2024
|
PC3I Authors Ronac Mamtani |
European Urology
|
|
Author Correction: Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial
|
January 19, 2024
|
PC3I Authors Ronac Mamtani |
Nature Medicine
|
|
Analysis of BRCA1- and BRCA2-Related Pancreatic Cancer and Survival
|
November 27, 2023
|
PC3I Authors Ronac Mamtani |
JAMA Network Open
|
|
The association between telemedicine, advance care planning, and unplanned hospitalizations among high-risk patients with cancer
|
November 21, 2023
|
PC3I Authors Peter Gabriel; Ronac Mamtani |
Cancer
|
|
Temporal changes in treatment patterns by age group and functional status before and after PD-1/L1 inhibitor approvals in advanced urothelial carcinoma
|
October 18, 2023
|
PC3I Authors Ronac Mamtani |
Frontiers in Oncology
|
|
Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial
|
October 2, 2023
|
PC3I Authors Ronac Mamtani |
Nature Medicine
|
|
Tumor Differentiation as a Prognostic Marker in Clinically Staged T1bN0 Esophageal Adenocarcinoma
|
September 4, 2023
|
PC3I Authors Ronac Mamtani |
Cancer Investigation
|
|
Brief Report: Second-line treatment outcomes in patients with advanced NSCLC previously treated with first-line immunotherapy regimens
|
July 14, 2023
|
PC3I Authors Charu Aggarwal; Christopher A. D’Avella; Ronac Mamtani; Melina Marmarelis |
Clinical Lung Cancer
|
|
Association Between Duration of Immunotherapy and Overall Survival in Advanced Non-Small Cell Lung Cancer
|
June 4, 2023
|
PC3I Authors Charu Aggarwal; Melina Marmarelis; Ronac Mamtani |
JAMA Oncology
|
|
Inverse Probability of Treatment Weighting and Confounder Missingness in Electronic Health Record-based Analyses: A Comparison of Approaches Using Plasmode Simulation
|
May 8, 2023
|
PC3I Authors Ronac Mamtani |
Epidemiology
|
